EMEA-001429-PIP01-13-M02

  • Email
  • Help

Overview

Product details for Besponsa
Invented nameBesponsa
Active substance

inotuzumab ozogamicin

Decision numberP/0402/2017
PIP numberEMEA-001429-PIP01-13-M02
Pharmaceutical form(s)Powder for concentrate for solution for infusion
Condition(s)/indication(s)

Treatment of B cell acute lymphoblastic leukaemia

Route(s) of administrationIntravenous use
PIP applicant

Pfizer Ltd  
Tel. +44 (0)1304 646607 
E-mail: pip_enquiries@pfizer.com

Decision typePM: decision on the application for modification of an agreed PIP

Decision

Related information